A beneficial gut bacterium common in infancy that mostly fades from the adult gut. A commercial strain has eased digestive discomfort and lowered body-wide inflammation, of interest for healthy aging. Much support comes from infant and laboratory studies, so adult longevity claims stay preliminary. Safety is favorable, with serious concerns limited to the seriously ill. (Full Review)

Protocol

Dose

1 billion CFU once daily

35624 (Align) dose; EVC001 typically ~8 billion CFU/day

Timing

With or after a meal

Once daily; a consistent time matters more than the hour

Duration

Ongoing daily use

Transient in adults; largely cleared within days of stopping

Time to effect

Digestion

2–4 weeks

Digestive comfort changes

Inflammation

6–8 weeks

Inflammatory-marker changes

Full trial

≥8 weeks

Before judging benefit

Benefits

Medium: Digestive comfort and irritable bowel symptom relief; lower body-wide inflammation

Low: Immune resilience and fewer common infections; gut barrier integrity and short-chain fatty acid supply

Speculative: Neuroprotection, mood, and cognition; metabolic and glycemic support; healthy aging via microbiome restoration

Contraindications

Severe immunosuppression

Critical illness

Central venous catheter

Short-bowel syndrome

Key Interactions

Antibiotics (amoxicillin, ciprofloxacin, metronidazole)

Antifungal and antiparasitic agents

Immunosuppressant drugs (corticosteroids, calcineurin inhibitors, chemotherapy)

Antacids and proton-pump inhibitors

Fecal microbiota transplantation and gut cleanses

Risk & Side Effects

Medium: Transient gastrointestinal symptoms

Low: Invasive infection in immunocompromised or critically ill individuals; product quality, viability, and mislabeling

Speculative: D-lactic acidosis and metabolic effects; symptom aggravation in bacterial overgrowth

Monitoring

Marker	Target	Why
High-sensitivity C-reactive protein	Below 1.0 mg/L	Tracks the body-wide inflammation this strain may lower
Fecal calprotectin	Below 50 µg/g	Reflects gut-lining inflammation relevant to digestive benefit
Comprehensive stool microbiome analysis	Detectable, balanced Bifidobacterium presence	Shows whether the strain and overall bifidobacteria are established
Fasting glucose and HbA1c	Glucose 70–90 mg/dL; HbA1c below 5.4%	Screens the speculative metabolic effects

Cadence: Recheck inflammatory markers after about 8–12 weeks of consistent use, then every 6–12 months if continued

Qualitative Assessment

Digestive comfort: frequency and severity of bloating, gas, and abdominal discomfort
Bowel regularity: stool consistency and predictability
Energy and vitality: subjective energy levels
Skin and general well-being: inflammatory skin flares or overall sense of well-being

Bifidobacterium infantis for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment